Oct 2026· Bleeding Thrombosis and Vascular Biology· Vol 5· 0 citations· 138 references
TL;DR
Despite major efforts by experts, who recently summarized their recommendations in the International Guidelines on VWD diagnosis and therapy, there are still many unmet needs in this disease management.
Abstract
Since the first description of the von Willebrand disease (VWD) families by Erik von Willebrand in 1926, VWD has been considered an inherited bleeding disorder completely different from hemophilia, already known for many years. The pivotal role of the adhesive glycoprotein von Willebrand factor in the early phases of hemostasis has been progressively unraveled in numerous publications. Still, actual progress in the clinical management of patients with VWD has always lagged that achieved in patients with hemophilia. After the pioneering studies of the first 50 years (1926-1975), the pathophysiology and diagnostics of patients with VWD became better distinguished from those with hemophilia. However, only in the last 50 years (1976-2025) have the basic and clinical aspects of VWD been clearly defined, with the scientific contributions of Italian investigators. Thanks to their research in collaboration with colleagues from Europe and the US, management of VWD patients improved significantly. In this review article, the most important milestones achieved in the diagnosis and treatment of VWD will be presented. Despite major efforts by experts, who recently (2021) summarized their recommendations in the International Guidelines on VWD diagnosis and therapy, there are still many unmet needs in this disease management. Indeed, the recommendations of the International Guidelines must be translated into current national practice by using a simplified diagnostic approach, as proposed recently by the joint AICE (Italian Association of Hemophilia Centers) and SISET (Italian Society for the Study of Hemostasis and Thrombosis) Italian Guidelines and by organizing structured clinical observation not only of severe VWD but especially of the more frequent mild-to-moderate types.
INTRODUCTION
von Willebrand disease (VWD) is a prevalent bleeding disorder resulting from deficiencies and/or defects in von Willebrand factor (VWF). Accurately diagnosing VWD, particularly distinguishing between qualitative defects (types 2A, 2B, 2 M, and 2N) and quantitative defects (types 1 and 3), poses challenges...
E. Favaloro, Sandya Arunachalam, Mahzuza Salwa et al.· Haemophilia· 0 citations
Introduction. Hemophilia A and von Willebrand disease (VWD) are the most common inherited bleeding disorders, resulting from low or dysfunctional factor VIII (FVIII) and von Willebrand factor (VWF), respectively. The purpose of the following analysis is to quantify the potential savings through desmopressin (DDAVP) use...
Alessandro Gringeri· Bleeding Thrombosis and Vasc...· 0 citations
Type 3 von Willebrand disease (VWD3) is due to a virtually complete deficiency of von Willebrand factor (VWF), and it is inherited as an autosomal recessive trait: heterozygous relatives have mild or no bleeding symptoms. The prevalence of VWD3 is very low, ranging from 0.1 to 5.3 per million population. VWD3 patients...
L. Baronciani, A. Federici, J. Eikenboom· Textbook of von Willebrand D...· 5 citations
Background. Desmopressin (DDAVP) has always been considered the treatment of choice for patients with mild/moderate von Willebrand disease (VWD), but no standardized criteria have been reported so far to predict the benefits/limits of DDAVP in the management of a very large cohort of VWD.Aims. To establish correct indi...
A. B. Federici· Bleeding Thrombosis and Vasc...· 0 citations
Background. Subcutaneous and intranasal desmopressin is safe and effective in type 1 VWD and particularly convenient for pediatric use and home treatment. Thus, it can reduce in-hospital admissions and inherent costs and favor adherence and the prompt control of bleeding. Nevertheless, it is often underused or unavaila...
Alessandro Gringeri· Bleeding Thrombosis and Vasc...· 0 citations
Benefits of long-term prophylaxis (LTP) in patients with severe von Willebrand disease (VWD) were well established by several studies. However, data on treatment modalities to gain optimal dosing and infusion schedule are limited.
To assess the efficacy and safety of LTP with a plasma-derived von Willebrand...
Cédric Hermans, B. Meddeb, Q. Van Thillo et al.· Therapeutic Advances in Hema...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.